{
  "first_published_at": "2007-08-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079104", 
  "title": "Isotretinoin for severe acne: access arrangements", 
  "tags": "{\"parsed_therapeutic\": [\"dermatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Dermatology\"]}", 
  "_document_number": 329, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "dermatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Isotretinoin for severe acne: access arrangements</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2007</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Isotretinoin should be prescribed only by consultant dermatologists or in consultant dermatologist-led teams, and dispensed only by a hospital pharmacy<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The prescribing of isotretinoin (brand leader Roaccutane) for the treatment of severe acne has been restricted to dermatologists since it was first authorised in the UK. Because of its known teratogenicity, additional precautions were introduced in 2005 for female patients through the Pregnancy Prevention Programme.</p><p>Given the availability of new generic isotretinoin products, it is important to ensure that healthcare professionals who prescribe and dispense isotretinoin are fully aware of these controls, particularly in light of a change to the Summary of Product Characteristics as a result of a European review.</p><p>The Marketing Authorisations or licences for isotretinoin products currently state that it can be prescribed by, or under supervision of, \"physicians with expertise in the use of systemic retinoids\". In the UK, this definition refers to consultant dermatologists.</p><p>Isotretinoin should be prescribed only by a consultant dermatologist-led team, and prescriptions should be issued under the consultant&rsquo;s name from a hospital-based pharmacy. This way, specialists with the most experience can advise patients about the important safety issues associated with isotretinoin.</p><p>Further information about the prescribing restrictions and <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Isotretinoinforsevereacne/index.htm\" target=\"_blank\">key safety issues associated with the use of isotretinoin</a> are available on the MHRA website.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update August 2007; Vol 1, Issue 1: 9.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The prescribing of isotretinoin (brand leader Roaccutane) for the treatment of severe acne has been restricted to dermatologists since it was first authorised in the UK. Because of its known teratogenicity, additional precautions were introduced in 2005 for female patients through the Pregnancy Prevention Programme.</p><p>Given the availability of new generic isotretinoin products, it is important to ensure that healthcare professionals who prescribe and dispense isotretinoin are fully aware of these controls, particularly in light of a change to the Summary of Product Characteristics as a result of a European review.</p><p>The Marketing Authorisations or licences for isotretinoin products currently state that it can be prescribed by, or under supervision of, \"physicians with expertise in the use of systemic retinoids\". In the UK, this definition refers to consultant dermatologists.</p><p>Isotretinoin should be prescribed only by a consultant dermatologist-led team, and prescriptions should be issued under the consultant&#8217;s name from a hospital-based pharmacy. This way, specialists with the most experience can advise patients about the important safety issues associated with isotretinoin.</p><p>Further information about the prescribing restrictions and <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Isotretinoinforsevereacne/index.htm\" target=\"_blank\">key safety issues associated with the use of isotretinoin</a> are available on the MHRA website.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update August 2007; Vol 1, Issue 1: 9.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2007-08-01", 
  "date_last_modified": "2010-08-03", 
  "_assets": [], 
  "_item_id": 329, 
  "summary": "Isotretinoin should be prescribed only by consultant dermatologists or in consultant dermatologist-led teams, and dispensed only by a hospital pharmacy", 
  "body": "Article date: August 2007\n\nThe prescribing of isotretinoin (brand leader Roaccutane) for the treatment of severe acne has been restricted to dermatologists since it was first authorised in the UK. Because of its known teratogenicity, additional precautions were introduced in 2005 for female patients through the Pregnancy Prevention Programme.\n\nGiven the availability of new generic isotretinoin products, it is important to ensure that healthcare professionals who prescribe and dispense isotretinoin are fully aware of these controls, particularly in light of a change to the Summary of Product Characteristics as a result of a European review.\n\nThe Marketing Authorisations or licences for isotretinoin products currently state that it can be prescribed by, or under supervision of, \"physicians with expertise in the use of systemic retinoids\". In the UK, this definition refers to consultant dermatologists.\n\nIsotretinoin should be prescribed only by a consultant dermatologist-led team, and prescriptions should be issued under the consultant’s name from a hospital-based pharmacy. This way, specialists with the most experience can advise patients about the important safety issues associated with isotretinoin.\n\nFurther information about the prescribing restrictions and [key safety issues associated with the use of isotretinoin](http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Isotretinoinforsevereacne/index.htm) are available on the MHRA website.\n\n \n\nArticle citation: Drug Safety Update August 2007; Vol 1, Issue 1: 9.\n"
}